Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TTX-030 |
Synonyms | |
Therapy Description |
TTX-030 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound ENTPD1 (CD39), resulting in decreased ATP hydrolysis, which potentially leads to activation of T-lymphocytes and anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5012). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TTX-030 | TTX030|TTX 030 | Adenosine Targeting 23 CD39 Antibody 5 | TTX-030 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound ENTPD1 (CD39), resulting in decreased ATP hydrolysis, which potentially leads to activation of T-lymphocytes and anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5012). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03884556 | Phase I | Gemcitabine + Nab-paclitaxel + TTX-030 Docetaxel + TTX-030 Pembrolizumab + TTX-030 TTX-030 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Completed | USA | 0 |